Translational platforms for cancer and metabolic disease to help accelerate new drug development programs. Develops preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products.
1. Rapid development and commercialization of new drugs using its proprietary drug delivery technology. Targeting indications through the 505(b)(2) regulatory pathway. Products under development are FP-001 (prostate cancer), FP-004 (opiate drug addiction), FP-002 (acromegaly), and FP-008 (diabetic retinopathy).
2. Rationally-designed small molecule candidates, designed through medicinal chemistry screening and lead optimization. Products currently under development are FP-025 (asthma / chronic obstructive pulmonary disease) and FP-020 (Alport syndrome).
New drugs in clinical trials are FP-001 LMIS 50mg (prostate cancer), currently in a multinational multi-center phase III registration study in the US, Europe and Taiwan, and FP-025 (a small molecule MMP-12 inhibitor for the treatment of asthma / chronic obstructive pulmonary disease), in a First-in-Human Phase I study in Taiwan.
Foresee Pharmaceuticals also has a US office.
Development of humanized monoclonal antibodies for treating allergic disorders and cancers. Also biosimilars development.
Combines glycosphingolipid antigen and human monoclonal antibody technologies to develop cancer drugs.
Technology collaboration with the Biomembrane Institute (TBI) and Dr. Sen-itiroh Hakomori in the US.
The exclusive technology of Kyowa Hakko Kirin Co. obtained for the research of monoclonal antibody drugs.
Uses GNT-produced nano-scale gold to develop a gold-based drug delivery platform as well as gold reagents. Has developed new dosage-forms of GNT gold-based chemotherapy agents and targeted cancer drugs.
Developer of new drugs from botanical sources, especially anti-cancer and anti-atherosclerosis.
Lead drug is Antroquinonol, derived from Antrodia camphorata, a unique mushroom of Taiwan. IND status granted by US FDA in 2010, with Orphan Drug Designation granted in 2015.
Company has started a fermentation databank with major academic institutions in Taiwan providing fungus strains. Currently, 4000 fungus strains have been screened and stored in this databank.
Uses proprietary site-directed in-vitro immunization technology to produce human monoclonal antibodies for biotech drug development applications.
Pipeline comprised of therapeutic antibodies and immune cell therapy, all at pre-clinical development stage: anti-CD152 monoclonal antibodies (immune enhancing therapy for a variety of cancer indications), and monoclonal antibody drugs for treating sepsis (anti-inflammatory), influenza and rare diseases.
Has research collaboration with the University of Cologne, Germany, to research and develop novel chimeric antigen receptor (CAR) T cell therapies.
Taipei 115, Taiwan
Drug development company with a focus on immunology, developing drugs for conditions such as cancer, autoimmune diseases, osteoporosis, infectious, and central nervous system diseases, pathological blood clots, and rejection reaction in organ transplantation.
Immunwork has developed a technology platform to create a class of new drugs the company terms T-E pharmaceuticals. These new drug molecules contain both targeting (T) and effector (E) moieties. The technology can be used to prepare antibody-drug conjugates (ADCs0, bispecific and multi-specific antibodies, and various products in versatile configurations, which have improved product homogeneity, drug payloads, target-binding valency, and consistency in the manufacturing process. The T-E configurations are expected to achieve increased efficacy and safety.